Google’s Latest Stock Investments Could Change Our World

In partnership with

Tackle Your Credit Card Debt With 0% Interest Until Nearly 2027 AND Earn 5% Cash Back

Some credit cards can help you get out of debt faster with a 0% intro APR on balance transfers. Transfer your balance, pay it down interest-free, and save money. FinanceBuzz reviewed top cards and found the best options—one even offers 0% APR into 2027 + 5% cash back!

Learn How To Apply Now

Metsera Inc. (MTSR): Reimagining Obesity Treatment with AI

What’s the story?

Metsera is a biotech upstart that’s making serious waves in the fight against obesity—a health crisis that’s only growing. The company is all about next-generation peptides, specifically GLP-1 receptor agonists, which are the same class of drugs behind blockbusters like Ozempic and Wegovy. But Metsera isn’t just copying the playbook; they’re rewriting it.

Their lead candidate, MET-097i, is a once-monthly injectable that’s already showing better weight loss results and a longer half-life than the competition in early trials. That means fewer injections for patients and potentially better outcomes—a huge deal in a market where convenience and efficacy can make or break a drug4.

Why is Google interested?

Here’s where it gets really interesting: Google’s investment comes through GV (Google Ventures), the tech giant’s venture arm. GV has a track record of backing companies that harness AI and data science to disrupt healthcare, and Metsera fits that mold perfectly23. The company’s approach is deeply data-driven, using advanced analytics to identify the best candidates for their therapies and optimize clinical development.

Obesity is a massive, global problem, and the market for effective treatments is projected to reach $168 billion by 20333. Google’s expertise in AI, cloud computing, and health data could supercharge Metsera’s ability to personalize treatments and accelerate drug discovery. Plus, with healthcare moving toward precision medicine, Google wants a front-row seat—and a hand in shaping the future.

What’s the upside?

• Metsera raised over $500 million in less than a year and pulled off a $275 million IPO in February 202514. That’s a serious war chest for clinical development.

• Their science is strong: MET-097i posted 7.5% weight loss in just 36 days, outpacing even the leaders in the space4.

• The company’s pipeline isn’t just about weight loss—they’re exploring treatments for cardiovascular, metabolic, and possibly even neurological diseases.

The bottom line:
Metsera is a classic moonshot—high risk, but with the potential for massive reward if their therapies deliver. Google’s involvement signals real confidence in Metsera’s science and its AI-powered approach to drug development.

AST SpaceMobile (ASTS): The Space Race for Global Connectivity

What’s the story?

AST SpaceMobile is building something out of science fiction: a space-based cellular broadband network that connects directly to your regular smartphone, no fancy satellite phone required. Their BlueWalker 3 satellite has already made history by enabling 2G, 4G LTE, and even 5G calls directly from space to standard devices56.

The company’s vision? Eliminate cellular dead zones for good, bringing connectivity to the 5.5 billion mobile devices that lose coverage when you leave the city, drive through rural areas, or travel the world.

Why is Google interested?

In January 2024, Google joined AT&T and Vodafone in a $155 million strategic investment in AST SpaceMobile56. But this isn’t just a financial play—Google is collaborating with AST on product development, testing, and integrating SpaceMobile’s network with Android and related devices56. That’s a big deal: imagine your next Pixel phone seamlessly switching between terrestrial and satellite networks, keeping you connected anywhere on Earth.

For Google, this investment is about more than just phones. It’s about expanding the reach of its entire ecosystem—Android, Google Cloud, and even search and ads—into places where the internet barely exists today. It also aligns perfectly with Google’s long-standing mission to “organize the world’s information and make it universally accessible and useful.”

What’s the upside?

• AST SpaceMobile has more than 3,100 patents and operates the largest commercial communications array in low Earth orbit5.

• They’ve inked agreements with over 40 mobile network operators, representing more than 2 billion subscribers globally5.

• The technology could be a game-changer for emergency response, remote work, and digital inclusion.

The bottom line:
Google’s investment in AST SpaceMobile isn’t just about satellites—it’s about owning the future of global connectivity. If AST delivers, Google stands to benefit from a world where every smartphone is always online, everywhere.

Why These Bets Matter

Both Metsera and AST SpaceMobile are tackling huge, complex problems—obesity and global connectivity—that touch billions of lives. Google’s investments aren’t just financial; they’re strategic. By backing Metsera, Google is betting on AI to transform healthcare and deliver personalized, effective treatments for one of the world’s biggest health challenges. With AST SpaceMobile, Google is pushing the envelope on global internet access, ensuring its services—and the world’s information—are always within reach.

In short: these are bets on the future, and Google wants to be building it, not just watching from the sidelines.

Did you like this article? Let us know if you want to see more reports like this. Respond to us - we would love to hear from you.

Disclaimer:
The information provided in this article is for informational and educational purposes only and should not be construed as financial advice, investment advice, or a recommendation to buy or sell any securities. Investing in stocks involves risk, including the potential loss of principal. Always do your own research and consult with a qualified financial advisor or professional before making any investment decisions. The views expressed here are based on publicly available information and are not guaranteed to be accurate or complete.